US2010286239A1PendingUtilityA1

Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation

60
Assignee: TOPIGEN PHARMA INCPriority: Jun 17, 1998Filed: Oct 26, 2009Published: Nov 11, 2010
Est. expiryJun 17, 2018(expired)· nominal 20-yr term from priority
Inventors:Paolo Renzi
A61P 37/08A61P 35/00A61P 29/00C12N 15/1138A61K 38/00C12N 2310/315A61P 11/06
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present invention are used for treating and/or preventing asthma, allergy, hypereosinophilia, general inflammation or cancer. The oligonucleotides of the present invention are more specifically directed against nucleic acid sequences coding for a CCR3 receptor, a common sub-unit of IL-4 and IL-13 receptors, or a common sub-unit of IL-3, IL-5 and GM-CSF receptors.

Claims

exact text as granted — not AI-modified
1 . An antisense oligonucleotide for treating and/or preventing asthma or allergy, said oligonucleotide being directed against a nucleic acid sequence coding for a common beta subunit of the IL-3, IL-5 and GM-CSF receptors. 
     
     
         2 . The oligonucleotide of  claim 10 , wherein said oligonucleotide has a sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16. 
     
     
         3 . A pharmaceutical composition for treating and/or preventing asthma or allergy said composition comprising at least one antisense oligonucleotide as defined in  claim 1  or  2 , in association with a pharmaceutically acceptable carrier. 
     
     
         4 . A method for treating and/or preventing asthma or allergy in a subject comprising administering to the subject an oligonucleotide as defined in  claim 1  or  2 . 
     
     
         5 . A method for treating and/or preventing asthma or allergy in a subject comprising administering to the subject a pharmaceutical composition as defined in  claim 3 . 
     
     
         6 . A pharmaceutical composition comprising at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors and at least one oligonucleotide directed against a nucleic acid encoding a common subunit of the IL4 and IL-13 receptors. 
     
     
         7 . The pharmaceutical composition according to  claim 6 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16. 
     
     
         8 . The pharmaceutical composition according to  claim 6 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common subunit of the IL-4 and IL-13 receptors is selected from the group consisting of oligonucleotides listed in the sequence listings as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7. 
     
     
         9 . The pharmaceutical composition according to  claim 6 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16 and at least one oligonucleotide directed against a nucleic acid encoding a common subunit of the IL4 and IL-13 receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7. 
     
     
         10 . The pharmaceutical composition according to  claim 6 , further comprising at least one oligonucleotide directed against a nucleic acid encoding a CCR3 receptor. 
     
     
         11 . The pharmaceutical composition according to  claim 10 , wherein at least one oligonucleotide directed against a nucleic acid encoding a CCR3 receptor is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, and SEQ ID NO:23. 
     
     
         12 . A pharmaceutical composition comprising at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors and at least one oligonucleotide directed against a nucleic acid encoding a CCR3 receptor. 
     
     
         13 . The pharmaceutical composition according to  claim 10 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16. 
     
     
         14 . The pharmaceutical composition according to  claim 10 , wherein at least one oligonucleotide directed against a nucleic acid encoding a CCR3 receptor is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, and SEQ ID NO:23. 
     
     
         15 . The pharmaceutical composition according to  claim 10 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16 and at least one oligonucleotide directed against a nucleic acid encoding a CCR3 receptor is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, and SEQ ID NO:23. 
     
     
         16 . A method for treating and/or preventing asthma or allergy in a subject comprising administering to the subject a pharmaceutical composition as defined in  claim 6 . 
     
     
         17 . The method according to  claim 16 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listing as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16. 
     
     
         18 . The method according to  claim 16 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common subunit of the IL-4 and IL-13 receptors is selected from the group consisting of the oligonucleotides listed in the sequence listing as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7. 
     
     
         19 . The method according to  claim 16 , wherein at least one oligonucleotide directed against nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listing as SEQ ID NO:9, SEQ ID NO:10, 35 SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16; and at least one oligonucleotide directed against a nucleic acid encoding a common subunit of the IL-4 and IL-13 receptors is selected from the group consisting of the oligonucleotides listed in the sequence listing as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7. 
     
     
         20 . A method for treating and/or preventing asthma or allergy in a subject comprising administering to the subject a pharmaceutical composition as defined in  claim 10 . 
     
     
         21 . The method according to  claim 20 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16. 
     
     
         22 . The method according to  claim 20 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-4 and IL-13 receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7. 
     
     
         23 . The method according to  claim 20 , wherein at least one oligonucleotide directed against a nucleic acid encoding a CCR3 receptor is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, and SEQ ID NO:23. 
     
     
         24 . The method according to  claim 20 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16; at least one oligonucleotide directed against a nucleic acid encoding a common subunit of the IL-4 and IL-13 receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7; and at least one oligonucleotide directed against a nucleic acid encoding a CCR3 receptor is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, and SEQ ID NO:23. 
     
     
         25 . A method for treating and/or preventing asthma or allergy in a subject comprising administering to the subject a pharmaceutical composition as defined in  claim 12 . 
     
     
         26 . The method according to claim  34 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16. 
     
     
         27 . The method according to claim  34 , wherein at least one oligonucleotide directed against a nucleic acid encoding a CCR3 receptor is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, and SEQ ID NO:23. 
     
     
         28 . The method according to claim  34 , wherein at least one oligonucleotide directed against a nucleic acid encoding a common beta subunit of the IL-3, IL-5 and GM-CSF receptors is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID 10 NO:15 and SEQ ID NO:16; and at least one oligonucleotide directed against a nucleic acid encoding a CCR3 receptor is selected from the group consisting of the oligonucleotides listed in the sequence listings as SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, and SEQ ID NO:23.

Join the waitlist — get patent alerts

Track US2010286239A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.